<DOC>
	<DOC>NCT00954616</DOC>
	<brief_summary>In each of the 7 French areas that should be involved, patients aged 75 years and over from three different sectors will be included: the geriatric consultation unit (60%) and two kinds of nursing homes, private (20%) and state (10%). Outpatients will be included in chronological order; patients in nursing homes will be included at random. The patients and their families will be asked about the treatments received on the day of inclusion. The inclusion period will extend over a year. The investigating practitioners will be asked to fill in a questionnaire reporting the main clinical data, adverse effects occurrence, and information on the treatment given.</brief_summary>
	<brief_title>Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the Elderly</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Patients aged 75 years and over identified as having Alzheimer disease and who have been treated for more than 3 months with anticholinesterase and/or memantine Patients with decompensated chronic condition or acute phase disease</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Inappropriate Medications Associated</keyword>
	<keyword>Alzheimer's disease</keyword>
</DOC>